hotspot -WSS

hotspot

author：fashion 2025-08-23 08:56:54 - browse：25888

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： A pediatrician calls for Congress to pass the child tax credit deal

leisure time

WSS

There's an unseen cost to disruptive road

Wegovy leads to weight loss. Can it treat depression, too?

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

How generative AI ratchets up security threats for health systems

Pancreatic cancer early detection could be helped by AI

explore

hotspot

focus

Walensky prepares to leave CDC — and Congress — behind

Pumping milk in bathrooms at health conferences is common

Virginia high school admissions case could be legal follow

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Hepatitis C has a cure — but many Americans still lack access to it

TikTok, Instagram influencers need more rules for drug ads

In Memoriam: Notable people who died in 2023

Wegovy leads to weight loss. Can it treat depression, too?

Virginia high school admissions case could be legal follow

Merck CEO won’t testify in Senate, citing no expertise in drug prices

entertainment

Why you shouldn’t ask, “What country has the best health care?”

FDA sets aggressive timeline for overhauling inspection procedures

Pumping milk in bathrooms at health conferences is common

The inclusion problem at the heart of rehabilitation research

Flu vaccine reformulation won't be easy, manufacturers warn

10 reasons why health care startups fail

hotspot

Wikipedia

leisure time

focus